← Eichor
Study identifier: NCT04423484 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Therapeutic Recommendations for Nephroblastoma

Condition: Nephroblastoma  ·  Sponsor: French Africa Pediatric Oncology Group

PhaseN/A
Planned participants1000
Who can joinAll sexes, 6 Months to 18 Years
Healthy volunteersNo

About this study

The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.

This description comes directly from the study's public registry record.

Talk to the study team

BRENDA Ms MALLON, MSC  ·  0033142115411  ·  brenda.mallon@gustaveroussy.fr

Always discuss trial participation with your own doctor first.

Locations (7)

Centre Hospitalier Universitaire Pédiatrique Charles De GaulleOuagadougou, Burkina FasoRecruiting
CHU de Treichville à ABIDJANAbidjan, Abidjan Autonomous District, Côte d’IvoireRecruiting
CUK (Cliniques Universitaires de Kinshasa)Kinshasa, Democratic Republic of the CongoRecruiting
Cliniques Universitaires de Lubumbashi (CUL)Lubumbashi, Democratic Republic of the CongoRecruiting
HJRA, Hôpital universitaire Joseph Ravoahangy AndrianavalonaAntananarivo, MadagascarRecruiting
CHU Gabriel Touré (HGT)Bamako, MaliRecruiting
Hôpital Aristide Le Dantec, Avenue Pasteur, BP 3001Dakar, Dakar, SenegalRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04423484